

Investigator Gazetteer Report – Diseases / Conditions - Jan 2021

Diseases / Conditions under Trial: Globally

By Johan PE Karlberg, MD, PhD

<https://www.clinicaltrialmagnifier.org/>

Objective and Material

The objective of this report is to display the type of diseases / conditions of global industry-sponsored clinical trials.

The data represent industry-sponsored phase II/III clinical trials for a four year period, i.e. for trials registered with the US trial registry (clinicaltrials.gov) between January 1, 2017 to December 31, 2020.

Results

The results are shown in Table 1 and Table 2.

Therapeutic Areas

Table 1 provides information on the number of trials and subjects by therapeutic area over the four year period; Oncology (23.5%) is the leading area followed by Infectious Diseases (14.1%), Neurology (8.0%) and Endocrinology (6.4%).

Note, that both oncology and infectious disease trials include trials from most other therapeutic areas – such trials are only consider under one therapeutic area.

The high number of subjects for infectious disease trials reflects the ongoing large scaled vaccine trials, e.g. against Covid-19.

Table 1. Therapeutic area: Number of industry-sponsored phase II/III trials and subjects by therapeutic area over a period of four full consecutive years (2017.01-2020.12).

Area	Rank	Trials (n)	Trials (%)	Subjects (n)	Subjects ()
Oncology	1	1,692	23.51	448,189	13.01
Infectious	2	1,016	14.12	1,500,000	43.63
Neurology	3	575	7.99	153,785	4.46
Endocrinology	4	458	6.36	191,042	5.55
Dermatology	5	418	5.81	101,163	2.94
Cardiology	6	413	5.74	186,454	5.41
Gastroenterology	7	394	5.48	97,383	2.83
Healthy Subjects	8	309	4.29	77,604	2.25
Allergy	9	291	4.04	96,732	2.81
Psychiatrics	10	270	3.75	69,312	2.01
Rheumatology	11	257	3.57	79,336	2.30
Hematology	12	245	3.40	25,688	0.75
Respiratory	13	171	2.38	47,461	1.38
Ophthalmology	14	164	2.28	45,278	1.31
Orthopedists	15	109	1.51	13,855	0.40
Anesthesiology	16	104	1.45	221,454	6.43
Obstetrics & Gynecology	17	103	1.43	38,842	1.13
Healthy / Pharmacology	18	42	0.58	20,977	0.61
Immunology	19	38	0.53	4,607	0.13
Ear, Nose and Throat	20	29	0.40	5,300	0.15
Dental	21	26	0.36	3,377	0.10
Surgery	22	20	0.28	4,012	0.12
Genetics	23	13	0.18	880	0.03
Other	24	12	0.17	2,942	0.09

Investigator Gazetteer Report – Diseases / Conditions - Jan 2021

Diseases / Conditions

Table 2 provides information on the number of trials and subjects by disease / condition over the four year period; Lung Cancer, Covid-19 and Diabetes are the leading three diseases.

The top 50 diseases / conditions represent about half, or 57.3% of the total.

Table 2. Diseases / Conditions: Number of industry-sponsored phase II/III trials and subjects by disease / condition over a period of four full consecutive years (2017.01-2020.12). Rank 1-50.

Disease / Condition	Rank	Trials (n)	Trials (%)	Subjects (n)	Subjects (I)
ONC RESP: LUNG	1	292	4.06	83,155	2.41
INFECT RESP: COVID-19	2	274	3.81	620,905	18.03
ENDO DIABETES	3	232	3.22	134,045	3.89
RHEUM ARTHRITIS/GOUT	4	200	2.78	63,401	1.84
ONC BREAST	5	186	2.58	63,660	1.85
ONC HEM: LYMPHOMA	6	136	1.89	19,776	0.57
ALLERGY ECZEMA/DERMATITIS	7	133	1.85	41,245	1.20
ONC SOLID TUMOR/CANCER	8	113	1.57	22,963	0.67
DERM PSORIASIS	9	112	1.56	33,563	0.97
INFECT RESP: INFLUENZA/FLU	10	101	1.40	226,721	6.58
NEUR ALZHEIMER/DEMENT	11	98	1.36	33,460	0.97
ONC HEM: LEUKEMIA	12	94	1.31	16,986	0.49
ALLERGY ALLERGY	13	92	1.28	34,438	1.00
CARDIO CHOLESTEROL/LIPIDS	14	83	1.15	19,831	0.58
PSYCH DEPRESSION	15	79	1.10	21,538	0.63
CARDIO CARDIOMYOP/FAILURE	16	71	0.99	42,754	1.24
GI ULCERATIVE COLITIS	17	69	0.96	18,584	0.54
NEUR MIGRAINE/H-ACHE	18	69	0.96	43,651	1.27
ONC GI: ESOPHAGEAL/GASTRIC	19	69	0.96	26,176	0.76
ONC UROLOGY: PROSTATE	20	69	0.96	25,308	0.73
GI LIVER FATTY	21	68	0.94	15,038	0.44
ONC ENT: NPC	22	68	0.94	13,323	0.39
OPHTHAL MACULAR DEGENERATION	23	68	0.94	21,569	0.63
ONC OG: OVARY	24	67	0.93	17,277	0.50
NEUR MULTIPLE SCLEROSIS	25	64	0.89	27,903	0.81
NEUR PARKINSON	26	64	0.89	9,257	0.27
ONC UROLOGY: BLADDER	27	60	0.83	22,647	0.66
OPHTHAL DRY EYE	28	59	0.82	17,142	0.50
HEM ANEMIA	29	57	0.79	7,343	0.21
ONC GI: COLORECTAL	30	57	0.79	13,210	0.38
ONC GI: LIVER	31	57	0.79	19,780	0.57
GI CROHN	32	54	0.75	20,417	0.59
ONC HEM: MYELOMA	33	54	0.75	10,833	0.31
INFECT HIV/AIDS	34	53	0.74	19,247	0.56
ONC DERM: MELANOMA	35	53	0.74	15,119	0.44
RESP COPD	36	53	0.74	27,878	0.81
INFECT GI: HEPATITIS B	37	51	0.71	11,636	0.34
PSYCH SCHIZOPHRENIA	38	49	0.68	14,297	0.42
UROLOGY KIDNEY FAILURE	39	49	0.68	14,145	0.41
RESP CYSTIC FIBROSIS	40	47	0.65	6,126	0.18
DERM ACNE	41	43	0.60	18,217	0.53
HEM HAEMOPHILIA A/B	42	43	0.60	3,273	0.10
NEUR EPILEPSY/SEIZURE	43	43	0.60	5,532	0.16
HEALTHY/PHARM	44	42	0.58	20,977	0.61
NEUR NEUROPATHY	45	38	0.53	8,201	0.24
ONC CNS: GLIOMA	46	38	0.53	3,844	0.11
ONC GI: PANCREAS	47	38	0.53	8,473	0.25
ORTH MUSCULAR DISEASE	48	38	0.53	4,288	0.12
CARDIO HYPERTENSION PULM	49	37	0.51	4,196	0.12
OPHTHAL DIABETIC	50	37	0.51	10,899	0.32

Investigator Gazetteer Report – Diseases / Conditions - Jan 2021

Table 2. Cont. Rank 51-110.

Disease / Condition	Rank	Trials (n)	Trials (%)	Subjects (n)	Subjects ()
ANEST PAIN ACUTE	51	36	0.50	8,322	0.24
CARDIO THROMB/COAG	52	36	0.50	5,453	0.16
CARDIO HYPERTENSION	53	35	0.49	9,035	0.26
DERM WRINKLES	54	35	0.49	9,162	0.27
INFECT RESP: PNEUMOCOCCAL	55	35	0.49	36,151	1.05
NEUR MUSCULAR DYSTROPHY	56	35	0.49	2,422	0.07
ONC OG: CERVIX	57	35	0.49	19,999	0.58
OPHTHAL GLAUCOMA	58	35	0.49	10,552	0.31
RHEUM LUPUS ERYTHEM.	59	34	0.47	9,327	0.27
UROLOGY KIDNEY NEPHRITIS	60	34	0.47	4,389	0.13
NEUR ALS	61	32	0.44	4,773	0.14
ONC UROLOGY: KIDNEY	62	32	0.44	11,431	0.33
INFECT GI: HEPATITIS C	63	31	0.43	6,519	0.19
HEM HEMOGLOBINURIA	64	30	0.42	1,972	0.06
GI ESOPHAGITIS/REFLUX	65	29	0.40	7,211	0.21
INFECT RESP: SYNCYTIAL	66	29	0.40	35,217	1.02
CARDIO STROKE	67	28	0.39	20,743	0.60
DERM HAIR LOSS	68	28	0.39	6,071	0.18
ENDO OBESITY	69	28	0.39	28,553	0.83
GI BILIARY DISEASE	70	28	0.39	2,792	0.08
PSYCH ADHD	71	27	0.38	6,425	0.19
DERM PRURITUS	72	26	0.36	5,838	0.17
ONC GI: BILIARY	73	26	0.36	6,628	0.19
ONC OG: UTERUS	74	25	0.35	9,323	0.27
RESP PULMONARY FIBROSIS	75	25	0.35	6,247	0.18
ALLERGY RHINITIS	76	24	0.33	7,583	0.22
DERM SKIN DISEASE	77	24	0.33	1,911	0.06
HEM MYELOFIBROSIS	78	24	0.33	4,345	0.13
ANEST ANALGESIC	79	23	0.32	5,111	0.15
INFECT CNS: MENINGOCOCCAL	80	23	0.32	25,463	0.74
UROLOGY INCONTINENCE	81	23	0.32	9,520	0.28
ENDO METAB/NUTR	82	22	0.31	7,708	0.22
PSYCH INSOMNIA/SLEEP	83	22	0.31	6,242	0.18
RHEUM SPONDYLITIS	84	22	0.31	6,602	0.19
IMMUNE GRAFT VS. HOST	85	21	0.29	3,698	0.11
INFECT RESP: CORONA	86	21	0.29	14,605	0.42
CARDIO CORONARY/ISCHEMIC	87	20	0.28	36,336	1.05
CARDIO PERIPH VASC	88	20	0.28	9,252	0.27
INFECT UROLOGY: URINARY	89	20	0.28	11,841	0.34
OG ENDOMETRIOSIS	90	20	0.28	6,815	0.20
ALLERGY URTICARIA	91	19	0.26	6,208	0.18
GI LIVER CIRRHOSIS	92	19	0.26	4,467	0.13
NEUR MYASTHENIA GRAVIS	93	19	0.26	1,574	0.05
ONC HEM: MYELODYSPLASTIC	94	19	0.26	3,249	0.09
ANEST PAIN	95	18	0.25	4,453	0.13
CARDIO ARRHYT/FIBRILL	96	18	0.25	6,286	0.18
INFECT RESP: PNEUMONIA	97	18	0.25	9,431	0.27
OPHTHAL EYE DISEASE	98	18	0.25	1,954	0.06
ORTH JOINT DISEASE	99	18	0.25	2,028	0.06
UROLOGY KIDNEY DISEASE	100	18	0.25	981	0.03
DERM ANGIOEDEMA	101	17	0.24	1,054	0.03
GI GASTRIC ULCER/BLEEDING	102	17	0.24	4,902	0.14
INFECT GI: CLOSTRIDIUM	103	17	0.24	24,176	0.70
INFECT GI: ENTERITIS	104	17	0.24	10,015	0.29
OG INFERTILITY	105	17	0.24	7,570	0.22
PSYCH BIPOLAR	106	17	0.24	4,135	0.12
HEM ANEMIA SICKLE CELL	107	16	0.22	1,600	0.05
INFECT CANDIDIA	108	16	0.22	3,214	0.09
DERM ROSACEA	109	15	0.21	6,809	0.20
ENDO GROWTH HORMONE	110	15	0.21	2,153	0.06